|
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines.
The web pages are not kept up to date and are for demonstration purposes only.
For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
|
BACK TO LIST |
|
|
|
|||||||||||||||||||
| Condition | Onset Date | Status |
|---|---|---|
| Hyperlipidemia | 12-Apr-2024 | active |
| Prediabetes | 30-Mar-2007 | active |
| Chronic sinusitis | 28-Oct-2005 | active |
| Medication | Since | Form | Dosage | Reason |
|---|---|---|---|---|
| Simvastatin 10 mg oral tablet | 2025-05-03 | - | 1 tablet (10 mg) by mouth once daily | Hyperlipidemia |
| 72 HR Fentanyl 0.025 MG/HR Transdermal System | 2025-04-18 | - | Apply 1 patch (0.025 mg/hr) every 72 hours | - |
| Acetaminophen 300 mg and codeine phosphate 15 mg oral tablet | 2025-04-18 | - | 1 tablet (300 mg/15 mg) every 4 to 6 hours as needed for pain | - |
| Abuse-Deterrent 12 HR Oxycodone Hydrochloride 10 MG Extended Release Oral Tablet [Oxycontin] | 2025-04-18 | - | 1 tablet (10 mg) every 12 hours | - |
| 12 HR Hydrocodone Bitartrate 10 MG Extended Release Oral Capsule | 2025-04-18 | - | 1 capsule (10 mg) every 12 hours | - |
| Vaccine | Date |
|---|---|
| Influenza virus antigen only vaccine product | 18-Apr-2025 |
| Clostridium tetani toxoid antigen adsorbed only vaccine product | 12-Apr-2024 |
| Live attenuated Human alphaherpesvirus 3 only vaccine product | 12-Apr-2024 |
| Allergy/Intolerance | Onset Date | Status | Type | Reaction |
|---|---|---|---|---|
| Live attenuated Varicella-zoster vaccine | ? | active | ? |
| Active Planned Care / Goals | Start Date | Reason |
|---|---|---|
| Hyperlipidemia clinical management plan | 03-May-2024 | Hyperlipidemia |
|
||
| Therapy | 18-Mar-2014 | - |
| Diabetes self management plan | 30-Mar-2007 | Prediabetes |
|
| Vital Signs | 2025-04-18 | 2024-04-12 |
|---|---|---|
| Body Height | 151.1 cm | 151.1 cm |
| Pain severity - 0-10 verbal numeric rating [Score] - Reported | 1 {score} | 1 {score} |
| Body Weight | 63.6 kg | 63.6 kg |
| Body mass index (BMI) [Ratio] | 27.9 kg/m2 | 27.9 kg/m2 |
| Diastolic Blood Pressure | 83 mm[Hg] | 82 mm[Hg] |
| Systolic Blood Pressure | 111 mm[Hg] | 106 mm[Hg] |
| Heart rate | 100 /min | 95 /min |
| Respiratory rate | 16 /min | 15 /min |
| Recent Lab Observations | 03-MAY-2025 | Reference Range | Unit |
|---|---|---|---|
| Glucose [Mass/volume] in Blood | 73.9 | 70 - 140 | mg/dL |
| Urea nitrogen [Mass/volume] in Blood | 15.3 | 7 - 25 | mg/dL |
| Creatinine [Mass/volume] in Blood | 3.4 H | 0.6 - 1.3 | mg/dL |
| Calcium [Mass/volume] in Blood | 9.7 | 8.5 - 10.5 | mg/dL |
| Sodium [Moles/volume] in Blood | 137.4 | 135 - 145 | mmol/L |
| Potassium [Moles/volume] in Blood | 4.3 | 3.5 - 5.1 | mmol/L |
| Chloride [Moles/volume] in Blood | 105.7 | 98 - 108 | mmol/L |
| Carbon dioxide, total [Moles/volume] in Blood | 24.3 | 22 - 29 | mmol/L |
| Protein [Mass/volume] in Serum or Plasma | 7.8 | 6.3 - 8.3 | g/dL |
| Albumin [Mass/volume] in Serum or Plasma | 4.8 | 3.5 - 5.5 | g/dL |
| Globulin [Mass/volume] in Serum by calculation | 3.2 | 2 - 3.9 | g/L |
| Bilirubin.total [Mass/volume] in Serum or Plasma | 0.1 L | 0.3 - 1.2 | mg/dL |
| Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma | 23.2 L | 32 - 104 | U/L |
| Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 45.4 | 7 - 55 | U/L |
| Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33.6 | 10 - 40 | U/L |
| Cholesterol [Mass/volume] in Serum or Plasma | 208.4 H | 125 - 200 | mg/dL |
| Triglyceride [Mass/volume] in Serum or Plasma | 121.5 | 35 - 150 | mg/dL |
| Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay | 149.5 H | 0 - 130 | mg/dL |
| Cholesterol in HDL [Mass/volume] in Serum or Plasma | 50.0 | 40 - 60 | mg/dL |
| Device | Date (since) |
|---|---|
| Blood glucose meter (physical object) | 30-Mar-2007 |
| Home nebulizer (physical object) | 28-Oct-2005 |